An Open,Multi-Center,Phase II Clinical Trial tO Evaluate Efficacy and Safety oF TAXOL(PACLITAXEL),UFT,and LEUCOVORIN in Patients With Advanced Gastric Cancer
Since 1982,cancer has been the leading cause of death in Taiwan. In particular,gastric
cancer is the fourth leading cause of death in male cancer patients and the sixth for female
patients in 2000,accounting for an estimated 2,374 deaths. In recent years, the treatment of
gastric cancer patients has gradually been improving due to advances in early diagnosis and
surgical techniques. Although chemotherapy and radiation therapy have been used in either
the adjuvant or palliative setting, their values are still limited due to their unacceptable
toxicity or inadequate efficiency.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the response rate
Kun-Huei Yeh, M.D.,Ph.D.
Department of Oncology, National Taiwan University Hospital
Taiwan: Department of Health